Related references
Note: Only part of the references are listed.Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study
Tullia de Risi-Pugliese et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Efficacy of the anti-IL 17 secukinumab in refractory Behcet's syndrome: A preliminary study
Gerardo Di Scala et al.
JOURNAL OF AUTOIMMUNITY (2019)
The efficacy of omalizumab in Cutaneous Mastocytosis: A case series
Tiffany Hinojosa et al.
DERMATOLOGIC THERAPY (2019)
Development of alopecia in patients treated with dupilumab
Nolan J. Maloney et al.
DERMATOLOGIC THERAPY (2019)
The Effect of omalizumab in Mastocytosis Patients. Prospective double-blind, placebo-controlled multicentre study
Meike Distler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders
Simone Garcovich et al.
FRONTIERS IN PHARMACOLOGY (2019)
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa
L. Prussick et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Two Patients with Healing of Alopecia areata on Dupilumab
Laine Ludriksone et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2019)
Case of alopecia areata during dupilumab treatment for atopic dermatitis
Naoko Kanda et al.
JOURNAL OF DERMATOLOGY (2019)
IL-17A is not a treatment target in progressive vitiligo
Reinhart Speeckaert et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
Use of Dupilumab in the Treatment of Papuloerythroderma of Ofuji
Yuichi Teraki et al.
JAMA DERMATOLOGY (2019)
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
Noa Kremer et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study
Marc Scherlinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study
A. R. J. V. Vossen et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid
Talia James et al.
CLINICAL IMMUNOLOGY (2019)
The role of biologics in the treatment of chronic granuloma annulare
Alessandra Chen et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2019)
Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40
Tomoko Matsuda et al.
JOURNAL OF DERMATOLOGY (2019)
Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid
Masahiro Kamata et al.
JOURNAL OF DERMATOLOGY (2019)
Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review
Rachel G. Casseres et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Guselkumab in the treatment of severe hidradenitis suppurativa
M. Kovacs et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Response to ustekinumab in three pediatric patients with alopecia areata
Abdullah Aleisa et al.
PEDIATRIC DERMATOLOGY (2019)
Reduced Itch Associated With Dupilumab Treatment in 4 Patients With Prurigo Nodularis
Nicholas K. Mollanazar et al.
JAMA DERMATOLOGY (2019)
Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus
Sarfaraz Hasni et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Alopecia Areata After Treatment with Dupilumab
Shiva Yazdanyar et al.
DERMATITIS (2019)
Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid
Sebastien Menzinger et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab
Anna Schuch et al.
ACTA DERMATO-VENEREOLOGICA (2018)
Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata
A. -S. Darrigade et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Failure of rituximab in refractory erosive lichen planus
P. Tetu et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report
L. Thorlacius et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Pyoderma gangrenosum: a review of pathogenesis and treatment
Christine Ahn et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions
Chuang-Wei Wang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study
Jung Min Bae et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Biologics for pityriasis rubra pilaris treatment: A review of the literature
Monica Napolitano et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Eosinophilic annular erythema treated with dupilumab
Samantha C. Gordon et al.
PEDIATRIC DERMATOLOGY (2018)
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
Adam Schiffenbauer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Alopecia universalis in a patient with rheumatoid arthritis developed during treatment with adalimumab
P. Ostojic et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2018)
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behcet's Syndrome A Retrospective Study of Seventy Patients With Vascular Involvement
Giacomo Emmi et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases
Aniek Lamberts et al.
FRONTIERS IN IMMUNOLOGY (2018)
Diverse expression of TNF-alpha and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis
Fang Wang et al.
CLINICAL AND TRANSLATIONAL ALLERGY (2018)
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata
Emma Guttman-Yassky et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients
Hiroaki Iwata et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid
Alex Kaye et al.
JAMA DERMATOLOGY (2018)
Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients
Katharina Herberger et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2018)
Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus
Rita Quelhas da Costa et al.
JAMA DERMATOLOGY (2018)
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Fernando Henrique Carlos de Souza et al.
ADVANCES IN RHEUMATOLOGY (2018)
Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
Aikaterini Kyriakou et al.
DERMATOLOGY REPORTS (2018)
Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature
Ora Shovman et al.
CLINICAL RHEUMATOLOGY (2018)
A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis
J. Loget et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study
Caiyun You et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report
Burak Tekin et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2017)
Successful Treatment of Autoimmune Disease-Associated Pyoderma Gangrenosum With the IL-1 Receptor Antagonist Anakinra: A Case Series of 3 Patients
Celia Beynon et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2017)
Ustekinumab for Behcet's disease
Adrien Mirouse et al.
JOURNAL OF AUTOIMMUNITY (2017)
Development of bullous pemphigoid during secukinumab treatment for psoriasis
Po-Han Ho et al.
JOURNAL OF DERMATOLOGY (2017)
Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity
Nina van Beek et al.
JAMA DERMATOLOGY (2017)
Biosimilars: From Extrapolation into Off Label Use
Sizheng Zhao et al.
CURRENT PHARMACEUTICAL DESIGN (2017)
Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid
T. Hashimoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study
Peter C. Grayson et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments
Asli Bilgic Temel et al.
CASE REPORTS IN DERMATOLOGY (2017)
T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-) in patients with alopecia areata: association with clinical type and severity
Mona A. Atwa et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
J. L. Blok et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature
G. Balakirski et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Refractory Subcutaneous Sweet Syndrome Treated With Adalimumab
Ashwin Agarwal et al.
JAMA DERMATOLOGY (2016)
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa A Randomized Clinical Trial
Vassiliki Tzanetakou et al.
JAMA DERMATOLOGY (2016)
Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check
Shesha Prasad Ranganath et al.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2016)
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo
K. C. Webb et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Occurrence of Sweet syndrome under anti-TNF
Christopher Banse et al.
CLINICAL RHEUMATOLOGY (2015)
Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients
Freja Laerke Sand et al.
DERMATOLOGIC THERAPY (2015)
Propionibacterium acnes Promotes Th17 and Th17/Th1 Responses in Acne Patients
Magdalena Kistowska et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Acne conglobata and adalimumab: use of tumour necrosis factor- antagonists in treatment-resistant acne conglobata, and review of the literature
Z. Z. N. Yiu et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2015)
Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo
Mario Vaccaro et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2015)
Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab
Sofie Lieberoth et al.
CASE REPORTS IN MEDICINE (2015)
USE OF BIOLOGICS IN PM AND DM IN SWEDEN - A NATIONAL REGISTER STUDY
J. Svensson et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Innate Immune Cell-Produced IL-17 Sustains Inflammation in Bullous Pemphigoid
Sebastien Le Jan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Etanercept therapy for toxic epidermal necrolysis
Andrea Paradisi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Alopecia Universalis Successfully Treated With Adalimumab
Loren Gorcey et al.
JAMA DERMATOLOGY (2014)
Ustekinumab in the Treatment of Refractory Chronic Cutaneous Lupus Erythematosus: A Case Report
Christine Dahl et al.
ACTA DERMATO-VENEREOLOGICA (2013)
Successful Treatment of Lichen Planus with Adalimumab
Peter Hollo et al.
ACTA DERMATO-VENEREOLOGICA (2012)
Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: A new therapeutic approach to immune-mediated inflammatory diseases
D. Lipsker et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2012)
Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients
Chantal Bolduc et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2012)
Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus
D. Winchester et al.
LUPUS (2012)
Disseminated granuloma annulare: A cutaneous adverse effect of anti-TNF agents
SibaP Raychaudhuri et al.
INDIAN JOURNAL OF DERMATOLOGY (2012)
Successful Treatment of Subacute Lupus Erythematosus With Ustekinumab
Aieska De Souza et al.
ARCHIVES OF DERMATOLOGY (2011)
Role of interleukin-17 in the pathogenesis of vitiligo
D. A. Bassiouny et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2011)
Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret (R)) in a Case of Refractory Sweet's Syndrome
Nicolas Kluger et al.
DERMATOLOGY (2011)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
A. Delluc et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Granuloma annulare induced by anti-tumour necrosis factor therapy
P. V. Voulgari et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
A pathogenic role for IgE in autoimmunity: Bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice
Janet A. Fairley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Etanercept for the management of oral lichen planus
Noam Yarom
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2007)
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn et al.
GUT (2006)
Share Paper
